主动脉瓣置换术后妊娠的母体、瓣膜与胎儿结局
妊娠期母体死亡和瓣膜血栓仅见于机械瓣组,活产概率为71.7%,低于自体瓣、同种瓣和生物瓣组。组织瓣组母体与胎儿结局可接受,但研究未做统计学比较。
要点
- 妊娠期瓣膜相关再干预仅见于生物瓣组,发生率为2.7%。
- 机械瓣组妊娠期瓣膜血栓再干预率4.9%,母体死亡率1.1%。
- 机械瓣组活产概率71.7%,低于自体瓣90.6%、同种瓣92.3%、生物瓣82.9%。
核心结论
- 妊娠期母体死亡和瓣膜血栓仅发生于机械瓣置换后的女性。
- 肺动脉自体瓣、同种瓣或生物瓣置换后妊娠的母体与胎儿结局可接受,但未做统计学比较。
研究设计与样本
- 比较肺动脉自体瓣(Ross手术)、同种瓣、生物瓣和机械瓣置换后妊娠的结局。
- 采用广义线性混合模型计算妊娠期母体、瓣膜和胎儿结局的合并比例。
主要发现
- 生物瓣组妊娠期瓣膜相关再干预率为2.7%(95%CI 0.4-16.9),距主动脉瓣置换5.1±2.5年。
- 肺动脉自体瓣组(距置换7.7±4.2年)和同种瓣组(距置换4.1±3.3年)未观察到妊娠期瓣膜相关再干预。
- 机械瓣组(距置换8.1±4.5年)妊娠期瓣膜血栓再干预率为4.9%(95%CI 1.6-14.0),母体死亡率为1.1%(95%CI 0.2-7.6)。
- 机械瓣组活产概率为71.7%(95%CI 59.2-81.6),自体瓣组为90.6%(95%CI 72.4-97.3),同种瓣组为92.3%(95%CI 56.0-99.1),生物瓣组为82.9%(95%CI 53.3-95.4)。
临床怎么用
- 对需主动脉瓣置换的年轻女性,选择瓣膜替代物时应考虑妊娠期母体与胎儿风险。
- 机械瓣置换后妊娠需警惕瓣膜血栓和母体死亡风险,活产概率相对较低。
- 组织瓣(自体瓣、同种瓣、生物瓣)置换后妊娠结局可接受,但需关注瓣膜功能变化。
局限性
- 研究未对瓣膜类型间结局进行统计学比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the optimal valve substitute for young women requiring aortic valve replacement (AVR), allowing improved future valve-related outcomes for mother and foetus during pregnancy. METHODS: A systematic search was performed for publications between 1998 and 2025 reporting women experiencing pregnancy after AVR with a pulmonary autograft (Ross-procedure), homograft, bioprosthesis (xenograft), or mechanical valve. Pooled proportions were calculated to determine maternal, valvular and foetal outcomes during pregnancy using generalized linear mixed models. RESULTS: Thirteen studies reporting 356 pregnancies in 251 women (pooled mean age at pregnancy 29.1 ± 4.8 years) after AVR with a pulmonary autograft (70 women, 119 pregnancies), homograft (73 women, 99 pregnancies), bioprosthesis (37 women, 50 pregnancies), or mechanical valve (71 women, 88 pregnancies) were included. During pregnancy, valve-related reintervention in women with a bioprosthesis was 2.7% (95% CI, 0.4-16.9) at 5.1 ± 2.5 years after AVR. This was not observed in women with pulmonary autografts (7.7 ± 4.2 years after AVR) and homografts (4.1 ± 3.3 years after AVR). Reintervention for valve thrombosis (4.9% [95% CI, 1.6-14.0]) and maternal death (1.1% [95% CI, 0.2-7.6]) occurred only in women with mechanical valves (8.1 ± 4.5 years after AVR). Pooled probability of liveborn delivery was 71.7% (95% CI, 59.2-81.6) in women with a mechanical valve, compared to 90.6% (95% CI, 72.4-97.3), 92.3% (95% CI, 56.0-99.1), and 82.9% (95% CI, 53.3-95.4) in women with an autograft, homograft, and bioprosthesis respectively. CONCLUSIONS: Maternal mortality and valve thrombosis during pregnancy occurred only in women with mechanical valves. Although no statistical comparisons were made, pregnancies in women with pulmonary autograft, homograft or bioprosthesis showed acceptable maternal and foetal outcomes. These descriptive findings provide foundations for further investigation of tissue-valve function before, during and after pregnancy, aiming for more support of current guidelines.
引用
- Khargi SDM, Grashuis P, Veen KM, et al. Maternal, Valvular and Foetal Outcomes of Pregnancy Following Aortic Valve Replacement. Eur J Cardiothorac Surg. 2026. PMID: 41886348. doi:10.1093/ejcts/ezag137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。